Organogenesis Holdings (ORGO) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Organogenesis published the results on November 5, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Revenue on this page is total revenue. In Q3 2025 it included $0.4 million of grant income on top of $150.5 million of net product revenue; Q3 2026 had no grant income.
• Net loss per share is calculated on net loss attributable to common stockholders of $32.8 million, after accretion and cumulative dividends on Organogenesis's Series A redeemable convertible preferred stock.

Source: Organogenesis Q3 2026 results, November 5, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Organogenesis splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Organogenesis's Advanced Wound Care revenue was $38.2 million in Q3 2026, down 73% from $141 million in Q3 2025, 84% of total revenue.
• Organogenesis's Surgical & Sports Medicine revenue was $7.3 million in Q3 2026, down 19% from $9.0 million in Q3 2025, 16% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Organogenesis said:

“Total net revenue between $179.4 million and $200.0 million, representing a decline in the range of 65% to 68%, as compared to total net revenue of $564.2 million for the year ended December 31, 2025.”

“Our updated total revenue guidance continues to reflect the expectation that we see sequential improvement in our revenue trends in the fourth quarter, however, at a more measured rate versus what our prior guidance assumed”

Source: Organogenesis Q3 2026 release, Nov 5, 2026.

This is the company's own guidance as of Nov 5, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the ORGO forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

Total revenue and diluted net income (loss) per share, each as first reported in that quarter's release. Q2 2026 includes a tax charge from setting up a full valuation allowance against deferred tax assets.

We do not hold a confirmed date for Organogenesis's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 5, 2026

Organogenesis sells regenerative medicine products, such as skin substitutes and placental allografts, to hospitals, wound care centers, surgery centers and physician offices. Net product revenue fell 70% to $45.5 million in Q3 2026 from $150.5 million. Advanced Wound Care, its main business, fell 73% to $38.2 million, and Surgical & Sports Medicine fell 19% to $7.3 million. (Organogenesis Q3 2026 release, Nov 5, 2026; Organogenesis Form 10-Q, Q3 2026, Nov 5, 2026)

Organogenesis attributes the drop to continued clinician confusion and material disruption in the market after Medicare contractors withdrew their LCD coverage policies for skin substitutes and CMS published comments on discarded product in December 2025. From 2026, CMS pays for certain skin substitutes at about $127.14 per square centimeter as incident-to supplies, with products grouped by FDA status into 361 HCT/Ps, PMAs and 510(k)s. (Organogenesis Form 10-Q, Q3 2026, Nov 5, 2026)

Organogenesis CEO Gary S. Gillheeney, Sr. said third-quarter revenue increased sequentially and that market share gains were broad-based across the portfolio. Surgical & Sports Medicine fell less steeply than wound care: down $1.7 million, against $103.3 million for Advanced Wound Care. For the first nine months, net product revenue was $124.5 million, down 63%. (Organogenesis Q3 2026 release, Nov 5, 2026)

Organogenesis's business is almost entirely domestic: net product revenue from outside the United States was 1% of the total in every period presented. It sells through a direct wound care sales force and, in Surgical & Sports Medicine, through independent agencies as well. (Organogenesis Form 10-Q, Q3 2026, Nov 5, 2026)

Organogenesis lost $29.6 million in Q3 2026, or $0.25 per share, after earning $21.6 million, or $0.11, a year earlier. Gross margin fell to 52% from 76% as revenue dropped faster than cost of goods sold, which declined 40% to $21.9 million. Selling, general and administrative expense was cut 43% to $45.1 million and R&D 40% to $8.0 million, leaving an operating loss of $29.5 million against operating income of $20.7 million. (Organogenesis Q3 2026 release, Nov 5, 2026)

Organogenesis's per-share loss is calculated on $32.8 million attributable to common stockholders, after $3.0 million of cumulative dividends and $0.2 million of accretion on its Series A redeemable convertible preferred stock. Weighted-average shares were 128,990,436. Income tax was negligible in the quarter because Organogenesis set up a full valuation allowance against its deferred tax assets in Q2 2026, which produced a nine-month tax expense of $30.1 million. (Organogenesis Q3 2026 release, Nov 5, 2026; Organogenesis Form 10-Q, Q3 2026, Nov 5, 2026)

Organogenesis reports adjusted net loss but no adjusted figure per share. Adjusted net loss was $29.3 million against adjusted net income of $23.2 million, and the Adjusted EBITDA loss was $22.4 million against income of $30.1 million. Adjusted net loss adds back $0.4 million of intangible amortization, and Adjusted EBITDA also adds back $2.8 million of stock-based compensation along with interest, tax and $3.9 million of depreciation. (Organogenesis Q3 2026 release, Nov 5, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Organogenesis updated its 2026 outlook and now expects total net revenue of $179.4 million to $200.0 million, a decline of 65% to 68% from $564.2 million in 2025. It still expects revenue to improve sequentially in the fourth quarter, at a more measured rate than its prior guidance assumed, putting the second-half decline at about 68% to 74% year over year, against the 64% to 74% its prior guidance assumed. (Organogenesis Q3 2026 release, Nov 5, 2026)

Total revenue for the first nine months of 2026 was $126.4 million, so the range implies fourth-quarter revenue of about $53 million to $74 million, against $45.5 million in Q3 2026. (Organogenesis Q3 2026 release, Nov 5, 2026)

A consensus figure is the average of the models published by the analysts who cover Organogenesis, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Organogenesis's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning ORGO is on is ORGO a buy or a sell?, what analysts expect next is on the ORGO forecast, and what the company does is on the Organogenesis Holdings (ORGO) stock page.

Every number on this page can be traced to a document Organogenesis published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.